By Mauro Orru

Roche Holding AG said Thursday that a Phase 3 REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe Covid-19 pneumonia didn't meet its primary endpoint of improved time to hospital discharge.

The Swiss pharmaceutical major also said the trial didn't meet key secondary endpoints compared with Veklury alone, but no new safety signals were identified for Actemra/RoActemra in the trial, conducted with Gilead Sciences Inc.

Roche said it would continue to assess data from the REMDACTA, COVACTA and EMPACTA studies as well as other studies of Actemra/RoActemra in Covid-19 pneumonia.

Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94

(END) Dow Jones Newswires

March 11, 2021 01:37 ET (06:37 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Roche (QX) Charts.